UNASSIGNED: Lowering low-density lipoprotein @entity165 ( @entity11429 ) reduces @entity65 ( @entity65 ) morbidity and mortality. Statins are the treatment of choice for lowering @entity11429 but a considerable number of @entity1 treated with @entity6817 are unable to achieve @entity11429 target values and many are statin-intolerant. New @entity11429 -lowering drugs - antibodies to @entity756 (alirocumab, evolocumab and bococizumab) - have been developed and are being tested in large clinical trials. They further reduce @entity11429 above maximally tolerated statin therapy by up to > 70%; they also reduce Lp(a), non-HDL-C, @entity755 , and modestly increase HDL-C. These drugs are well tolerated and even @entity1 who achieved very low @entity11429  <= 0.65 mmol/l (    25 mg/dl) did not have any significant adverse effects. Treatment with @entity756 inhibitors resulted in @entity11429 target values in 70 - 90% of @entity1 according to the guidelines. However, although @entity756 inhibitors seem to be the most promising emerging therapeutic option for @entity11429 lowering today, outcome data with endpoints on their effects are still lacking. Another important open question is their long-term safety. Their use in statin-intolerant @entity1 also raises questions, as the criteria for statin-intolerance are neither clear nor generally accepted. The presumed high cost of @entity756 inhibitors might be an obstacle for their broader use.

XXXX inhibitors - past, present and future.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity756 :: ('255738', 'Gene') :: ['PCSK9'] @entity6817 :: ('D019821', 'Chemical') :: ['statins'] @entity755 :: ('338', 'Gene') :: ['apolipoprotein-B'] @entity11429 :: ('22796', 'Gene') :: ['LDL-C'] @entity65 :: ('MESH:D002318', 'Disease') :: ['CVD', 'cardiovascular disease'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity756 :: (255738,Gene) :: ['PCSK9']
